Beuers U - Search Results

1

Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Munoz-Garrido P, Marin JJ, Perugorria MJ, Urribarri AD, Erice O, Sáez E, Úriz M, Sarvide S, Portu A, Concepcion AR, Romero MR, Monte MJ, Santos-Laso Á, Hijona E, Jimenez-Agüero R, Marzioni M, Beuers U, Masyuk TV, LaRusso NF, Prieto J, Bujanda L, Drenth JP, Banales JM. Munoz-Garrido P, et al. Among authors: beuers u. J Hepatol. 2015 Oct;63(4):952-61. doi: 10.1016/j.jhep.2015.05.023. Epub 2015 Jun 1. J Hepatol. 2015. PMID: 26044126 Free PMC article.

2

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.

Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G. Beuers U, et al. Hepatology. 1992 Apr;15(4):603-8. doi: 10.1002/hep.1840150409. Hepatology. 1992. PMID: 1551637

3

Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man.

Beuers U, Fischer S, Spengler U, Paumgartner G. Beuers U, et al. J Hepatol. 1991 Jul;13(1):97-103. doi: 10.1016/0168-8278(91)90870-h. J Hepatol. 1991. PMID: 1918882

4

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.

Paumgartner G, Beuers U. Paumgartner G, et al. Among authors: beuers u. Hepatology. 2002 Sep;36(3):525-31. doi: 10.1053/jhep.2002.36088. Hepatology. 2002. PMID: 12198643 Review.

5

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.

Beuers U. Beuers U. Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28. doi: 10.1038/ncpgasthep0521. Nat Clin Pract Gastroenterol Hepatol. 2006. PMID: 16741551 Review.

6

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.

Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. Cullen SN, et al. Among authors: beuers u. J Hepatol. 2008 May;48(5):792-800. doi: 10.1016/j.jhep.2007.12.023. Epub 2008 Feb 14. J Hepatol. 2008. PMID: 18314215 Clinical Trial.

7

Overlap syndromes among autoimmune liver diseases.

Rust C, Beuers U. Rust C, et al. Among authors: beuers u. World J Gastroenterol. 2008 Jun 7;14(21):3368-73. doi: 10.3748/wjg.14.3368. World J Gastroenterol. 2008. PMID: 18528934 Free PMC article. Review.

8

EASL Recognition Awardee 2009: Prof. Raoul Poupon.

Beuers U. Beuers U. J Hepatol. 2009 Oct;51(4):617-9. doi: 10.1016/j.jhep.2009.07.004. J Hepatol. 2009. PMID: 19760809 No abstract available.

9

Bile salts and cholestasis.

Maillette de Buy Wenniger L, Beuers U. Maillette de Buy Wenniger L, et al. Among authors: beuers u. Dig Liver Dis. 2010 Jun;42(6):409-18. doi: 10.1016/j.dld.2010.03.015. Dig Liver Dis. 2010. PMID: 20434968 Review.

10

Lysophosphatidic acid is a potential mediator of cholestatic pruritus.

Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, Moolenaar WH, Beuers U, Oude Elferink RP. Kremer AE, et al. Among authors: beuers u. Gastroenterology. 2010 Sep;139(3):1008-18, 1018.e1. doi: 10.1053/j.gastro.2010.05.009. Epub 2010 Jun 19. Gastroenterology. 2010. PMID: 20546739

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

418 results

Search Page